Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| ASML Holding NV | 5.90% | $38.57M | €450.59B | 80.13% | 76 Outperform | |
| Novartis AG | 4.46% | $29.15M | CHF230.97B | 25.96% | 80 Outperform | |
| Roche Holding AG | 4.14% | $27.07M | CHF256.31B | 21.75% | 73 Outperform | |
| Advantest | 3.32% | $21.67M | ¥16.50T | 171.08% | 75 Outperform | |
| Rolls-Royce Holdings | 3.03% | $19.82M | £102.31B | 55.00% | 71 Outperform | |
| SAFRAN SA | 2.78% | $18.16M | €126.91B | 21.97% | 67 Neutral | |
| Allianz | 2.48% | $16.21M | €134.10B | 0.55% | 67 Neutral | |
| Unilever | 2.43% | $15.89M | £105.64B | ― | 72 Outperform | |
| ABB Ltd | 2.33% | $15.20M | kr1.45T | 36.87% | 78 Outperform | |
| GlaxoSmithKline | 2.23% | $14.57M | £81.32B | 34.41% | 77 Outperform |